Illumina, Inc.

ILMN Healthcare Diagnostics & Research

Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024.

Revenue
+4.15%
EPS
+49.0%
Free cash flow
+49.8%
Total debt
+80.0%

Quarter to September 2026, against a year earlier

209.82 16.72 −7.38%
Market cap
$31.5B
P/E
35.6×
Fwd P/E
46.4×
Dividend yield
—
F-score
8/9
Altman Z
4.39
Beneish M
−2.51
Dividend safety
n/a

Illumina, Inc. (ILMN) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Illumina, Inc. (ILMN) trades at a P/B ratio of 10.1×. Over the past ten years it has ranged from 2.4× (November 2023) to 19.0× (June 2015); the current reading is higher than 49% of that period. That is above the Diagnostics & Research industry median of 3.4× and above the Healthcare sector median of 2.3×.

P/B ratio, daily

Embed this chart

Annual newest first

Period P/B ratio Change
FY2025 7.5× (16.62%)
FY2024 9.0× 140.96%
FY2023 3.7× (20.81%)
FY2022 4.7× (10.06%)
FY2021 5.2× (54.14%)
FY2020 11.4× 9.61%
FY2019 10.4× (7.81%)
FY2018 11.3× (3.63%)
FY2017 11.7× 40.12%
FY2016 8.3× (43.07%)

Quarterly newest first

Period P/B ratio Change
Sep 2026 13.1× 40.46%
Jun 2026 9.4× 32.75%
Mar 2026 7.0× (5.61%)
Dec 2025 7.5× 22.34%
43 more quarters

Against its own ten years

Low 2.4× High 19.0×
Ten-year median 10.1×
Current reading's percentile 54

P/B ratio against peers

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

More on ILMN